In a recent update, Theravance Biopharma, Inc. (NASDAQ: TBPH) received a Neutral rating from Mayank Mamtani of B. Riley Securities on March 4, 2026. This assessment highlights a cautious outlook for investors, even as the stock is currently trading significantly below analysts’ price targets, suggesting considerable upside potential. With a current price of $13.96 and a price target averaging $28, investors may be pondering the implications of this rating change amid the company’s recent performance.
Recent Price Action
Theravance Biopharma’s stock has shown some fluctuation in recent trading sessions, closing down slightly by $0.03, which translates to a decrease of approximately 0.21%. The company has a market capitalization of approximately $706 million and has registered a beta of 0.107, indicating lower volatility compared to the broader market. During the past week, TBPH stock has traded between a 52-week high of $13.5 and a low of $130.25, which reflects a significant decline from its highest trading points. The volume of shares traded on the latest session was about 408,985, compared to an average volume of 528,403, indicating a more muted trading environment which may signify investor caution as they await further developments.
Short- and Long-Term Performance
Analyzing Theravance’s stock performance over various time frames reveals a complex picture. Over the past 30 days, the stock has maintained a solid monthly performance of 14.01%, while its quarterly return has surged impressively by 43.2%. Furthermore, on a broader scale, the stock has delivered an extraordinary 141.94% increase over the past year. Despite weekly volatility at 4.95% and monthly volatility at 3.75%, this historical performance suggests a stock that, while currently consolidating, has also demonstrated remarkable resilience and growth amid challenging market conditions.
Earnings / Financials
The company’s latest earnings report revealed an EPS of $0.07, significantly beating the prior estimate of -$0.03. This notable surprise of 333.33% indicates a substantial upward swing in financial performance, especially in comparison to the previous quarter, when the EPS was reported at -$0.08 against an estimate of -$0.14. This consistency in outperforming estimates may suggest improvements in operational efficiency and revenue generation, positively affecting overall sentiment among investors.
Analyst / Consensus View
Overall sentiment among analysts paints a generally optimistic but cautious picture. Out of a total of four ratings, Theravance has garnered three “Buy” ratings and one “Hold,” with no “Sell” ratings reported. The average price target across analysts stands at $33.75, with a high estimate reaching $40 and a low estimate at $27. The recent downgrade to Neutral by B. Riley Securities, despite an enticing target of $28, indicates a need for investors to approach the stock with tempered expectations, particularly in the current market climate.
Stock Grading or Fundamental View
The Stocks Telegraph grade for Theravance Biopharma is 54, suggesting a moderate level of investment quality grounded in its overall financial strength and market positioning. This score encapsulates the company’s fundamentals and market performance, indicating that while Theravance may present attractive opportunities, there are underlying risks that warrant careful consideration.
Conclusion
For investors considering Theravance Biopharma, the stock may appeal primarily to those with a high tolerance for risk and a keen interest in growth potential. The stock’s considerable upside relative to recent price targets could attract growth-oriented portfolios, especially in light of recent earnings surprises. However, potential investors should remain vigilant regarding the uncertainties reflected in the recent neutral ratings from analysts and the broader market’s volatility. As always, thorough due diligence will be essential to navigate the potential rewards and risks associated with investing in TBPH.